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Hodgkin lymphoma (HL) represents one of the great success stories in hematology going 
from a uniformly fatal disease, to one that is curable in the vast majority of cases. Despite 
this success, some patients experience relapse. To address this unmet need a variety of 
agents, classes of drugs, and strategies have demonstrated activity in HL recurring after 
autologous hematopoietic stem cell transplantation. These include chemotherapeutics 
(gemcitabine-based combinations, bendamustine), histone deacetylase (HDAC) in-
hibitors (panobinostat), immunomodulatory agents (lenalidomide), mTOR inhiobitors 
(everolimus), monoclonal antibodies (rituximab), and antibody-drug conjugates 
(brentuximab vedotin) as well the potential of long-term disease control via allogeneic 
transplantation. Such advances reflect our increased understanding of the biology of HL 
and hold promise for continued improved outcomes for those suffering with this 
condition.
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INTRODUCTION
Hodgkin lymphoma (HL) newly presents in over 8,400 
individuals per year in the United States (US), accounting 
for approximately 8.7% of all lymphomas in the US, and 
is diagnosed worldwide in approximately 635,000 individuals 
annually [1, 2]. Over the past half century with advancements 
in radiation and chemotherapy, HL has evolved from a disease 
that was nearly uniformly fatal, to one that reaches a cure 
rate approaching 70-90% with initial therapy [3, 4]. For 
patients who relapse after initial therapy, the current stand-
ard of care is high dose chemotherapy followed by autologous 
hematopoietic stem cell transplant (auto-HCT), which has 
been shown to yield long-term remissions in approximately 
50% of patients with chemotherapy responsive disease [5, 
6]. However, in the subset of patients with refractory disease 
or relapse after auto-HCT, prognosis remains poor. The pur-
pose of this review will be to highlight current therapies 
in development for use in patients with relapsed/refractory 
HL who have failed auto-HCT, with an emphasis on novel 
combination chemotherapy regimens, biologic agents and 
the emerging role of reduced intensity conditioning alloge-
neic transplant (RIC allo-HCT).
TRADITIONAL CHEMOTHERAPEUTICS
1. Gemcitabine-based regimens
The development of combination chemotherapeutic agents 
for use in relapsed/refractory HL has centered on gemcitabine 
(difluorodeoxycytidine), a drug that has been shown to have 
success as single agent therapy with an overall response 
rate (ORR) of 39% [7]. The combination of gemcitabine, 
vinorelbine and pegylated liposomal doxorubicin (GVD) for 
relapsed/refractory HL has been evaluated for safety and 
efficacy by the Cancer and Leukemia Group B (CALGB) 
in a phase I/II trial, which included 91 patients (Table 1) 
[8]. The median age was 33, with 89 patients having classic 
HL (2 patients with lymphocyte predominant disease), and Korean J Hematol 2012;47:8-16.
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Table 1. Selected traditional chemotherapeutic regimens for relapsed Hodgkin lymphoma.
Regimen
No. of 
patients
Median age 
in years
Number of prior treatments
a) Prior transplant ORR% CR%
GVD [8] 91  33  Transplant naïve: 79% one prior treatment 40 (44%) 70% 19%
Prior transplant: 70% with 3 or more prior treatments
GDP [9] 23 36.5 At least 1 prior treatment; 26% refractory to ABVD   0 69.5% 17%
GCD [10] 14 32  2 (range 1-5)   4 86% 50%
Bendamustine [11] 18  -- -- 12 with prior auto-HCT 75% 38%
  2 with prior NMT
a)Excluding auto-HCT.
Abbreviations: No., number; ORR, overall response rate; CR, complete response; auto-HCT, autologous stem cell transplant; NMT, 
non-myeloablative stem cell transplant; GVD, gemcitabine, vinorelbine and pegylated liposomal doxorubicin; GDP, gemcitabine, 
dexamethasone and cisplatin; GCD, gemcitabine, carboplatin, and dexamethasone; ABVD, adriamycin, bleomycin, vinblastine, dacarbazine; 
--, data not available.
40 patients having had prior auto-HCT. Of the prior trans-
plant patients, 70% had 3 or more prior chemotherapy 
regimens. GVD was given on days 1 and 8 of a 21-day 
cycle. The major dose limiting side effect in patients without 
prior transplant was mucositis and febrile neutropenia in 
those with prior transplant. Not surprisingly, grade 3 or 
4 thrombocytopenia developed in 43% of prior transplant 
patients compared 14% of those without prior transplant. 
Three cases of AML/MDS occurred, all in patients with prior 
auto-HCT. The ORR was 70%, which included 51% with 
a partial response (PR) and 19% with a complete response 
(CR). At the maximum tolerated dose (MTD), ORR was 
61% for the transplant naïve group (25/41) and 75% (27/36) 
for the prior transplant group. In terms of event free survival 
(EFS), the median had not been reached in the transplant 
naïve group with 52% of patients without evidence of disease 
progression at 4 years, and in the prior transplant group, 
the median EFS was 8.5 months. In the transplant naïve 
group, median overall survival (OS) had not been reached 
at 4 years, with 70% still alive, and in the prior transplant 
group median OS was 3.5 years. Progressive HL was the 
main cause of death in most patients, occurring in 27 of 
36 that died [8]. Although outcomes were promising in the 
patients who had not undergone prior transplant, those had 
failed auto-HCT, despite a relatively high ORR, had a short 
median EFS, with progressive disease (PD) accounting for 
most deaths.
The combination of gemcitabine, dexamethasone and cis-
platin (GDP) has also been evaluated for relapsed/refractory 
HL (Table 1). In a prospective phase II study published by 
Baetz et al., 23 patients with relapsed/refractory HL were 
given gemcitabine 1,000 mg/m
2 IV on day 1 and 8, cisplatin 
75 mg/m
2 IV following gemcitabine and dexamethasone 40 
mg orally in divided doses on days 1-4 as part of a 21 day 
cycle [9]. The median age was 36.5, and at least 6 patients 
(26%) had failed to achieve a response with ABVD (Adriamy-
cin, bleomycin, vinblastine and dacarbazine). ORR was 70%, 
including 17% (4 patients) with a CR and 52% (12 patients) 
with a PR. GDP was well tolerated, with no deaths secondary 
to treatment, no cases of cases of febrile neutropenia and 
no platelet transfusions were required, although 4 patients 
did require red blood cell transfusions. Since all patients 
went on to undergo auto-HCT, specific data with the regimen 
in the post-transplant setting cannot be derived from this 
study.
The combination regimen of gemcitabine, carboplatin, and 
dexamethasone (GCD) was evaluated by the Seattle group 
for use in relapsed/refractory HL (Table 1) [10]. In this pro-
spective study, 51 patients with relapsed lymphoma were 
enrolled and evaluable, including 14 with HL. The median 
age of the HL patients was 32 and the median number of 
prior therapies was 2 (range, 1-5) with 4 relapsing after 
prior HCT (A. Gopal personal communication). Importantly, 
12 patients (86%) responded (7 CR/5 PR) including all 4 
patients with prior HCT (3 CR/1 PR). For those who at-
tempted peripheral blood stem cell mobilization following 
this regimen (N=7), the median CD34 collection was 
10.9×10
6/kg (range, 5.5-18.8×10
6 CD34/kg). These studies and 
others indicate the tolerability and potential efficacy of gem-
citabine-based regimens in patients with relapsed or re-
fractory HL and the variety of effective combinations can 
allow the treating physician to tailor the added agents to 
a patient’s specific needs and comorbidities (eg: neuropathy, 
renal insufficiency, marrow reserve, etc.).
2. Bendamustine
Bendamustine is a bi-functional alkylator that has been 
approved in the US and Europe for the treatment of relapsed 
indolent B-cell non-Hodgkin lymphoma (B-NHL) and 
chronic lymphocytic leukemia (CLL) [11]. In vitro data also 
suggest that bendamustine displays pro-apoptotic and an-
ti-proliferative effects on cultured HL cells [12]. Based on 
these preclinical results, investigators at the Memorial Sloan 
Kettering Cancer Center evaluated the efficacy of bendamus-
tine in a phase II study of patients with relapsed/refractory 
HL (Table 1) [13]. Preliminary data was reported on 18 
patients (out of planned 37) of whom 16 were evaluable. 
Of these, 12 had failed prior auto-HCT and 2 had failed 
prior non-myeloablative transplant (NMT). Patients were 
treated with bendamustine at a dose of 120 mg/m
2 for two 
consecutive days every 28 days and pegfilgrastim was ad-
ministered with each dose. Primary outcomes included re-Korean J Hematol 2012;47:8-16.
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Table 2. Selected biologic agents and small molecules for relapsed Hodgkin lymphoma.
Regimen
No. of 
patients
Median 
age
No. of prior 
treatments
a) Prior transplant ORR% CR%
Panobinostat [16] 129 32 4   10% prior allogeneic transplant 27%   4%
Lenalinomide [18] 38 34 4   87% (29 prior auto-HCT, 1 syngeneic, and 3 both allo and auto-HCT) 17%   3%
Everolimus [21] 19 37 6   84% 47%   5%
Rituximab [23] 22 35 4   82%  22%   4%
Brentuximab Vedotin [30] 102 31 4 100% 75% 34%
a)Excluding auto-HCT.
Abbreviations: No., number; ORR, overall response rate; CR, complete response; allo, allogeneic; auto-HCT, autologous stem cell transplant.
sponse rate and referral to NMT. The ORR was 75%, with 
6 patients (38%) achieving a CR, 6 patients (38%) achieving 
a PR and one patient with stable disease (SD). Two patients 
died prior to first re-evaluation secondary to PD. Adverse 
events (AEs) reported were pyelonephritis, fungal pneumo-
nia and grade 3 nausea. A total of 10 patients had either 
delays or reductions in treatment due to nausea, pneumonia, 
thrombocytopenia or neutropenia. Importantly, of the 12 
patients who were potentially eligible for NMT, 6 (50%) 
were successfully referred, although 3 patients ultimately 
refused. These early results suggest the potential of bend-
amustine for use in heavily pre-treated HL patients, however 
the final peer-reviewed update from this trial and additional 
studies are needed to clarify the safety and efficacy of this 
approach. Future strategies including the incorporation of 
bendamustine into combination regimens for HL are under-
way at our center and others.
BIOLOGICAL AGENTS AND SMALL MOLECULES
1. Panobinostat
A novel class of drugs under evaluation for use in re-
fractory/relapsed HL are the histone deacetylase inhibitors, 
with most of the data are derived from experience with 
panobinostat. Panobinostat is an orally bioavailable pan de-
acetylase inhibitor (pan-DACi) that has been clinically eval-
uated multiple malignancies and also been shown to have 
in vitro activity against cultured HL cell lines [14]. In phase 
IA/II study published by Dickinson et al., 13 patients with 
relapsed/refractory HL underwent treatment with panobino-
stat, with 58% (7/12) showing reduction in metabolic activity 
measured by PET response [15]. A large multi-center phase 
II trial, led by Sureda et al., was initiated to further evaluate 
the safety and efficacy of panobinostat (Table 2) [16]. At 
the time of abstract publication (American Society Hematol-
ogy, 2010), a total of 129 patients with relapsed/refractory 
HL had been enrolled and treated. The median age was 
32 with a median of 4 (2-7) prior treatments, and 10% had 
prior allo-HCT. Panobinostat was dosed 40 mg orally three 
times a week in a 21-day cycle with response evaluated 
by CT/MRI. The ORR was 27%, with 5 patients achieving 
a CR and 30 patients achieving a PR. A preliminary analysis 
showed median progression free survival (PFS) was 5.7+ 
months, a disease control rate o f  8 2 %  ( P R ,  C R  a n d  S D )  
and a duration of response (DOR) of 6.9+ months. Grade 
3/4 AEs included anemia, neutropenia and thrombocytope-
nia, typically reversible with holding or modifying the dose 
[16]. These results are encouraging, showing that Panobini-
stat in this heavily pre-treated population was not only toler-
able, but also resulted in durable responses, suggesting that 
this class of agents may play a role in the management of 
HL in the future.
2. Lenalidomide
Lenalidomide, a pro-apoptotic, anti-angiogenic and im-
munomodulatory agent approved for the treatment of certain 
hematologic malignancies (multiple myeloma and myelodys-
plastic syndrome with del5q), is also being investigated for 
use in refractory/relapsed HL. In a small phase II trial led 
by Kuruvilla et al., 15 patients, 14 of who were evaluable, 
were given 25 mg orally on days 1-21 of a 28-day cycle 
(Table 2) [17]. Grade 3-4 AEs included thrombocytopenia, 
anemia and neutropenia. Results showed PR in 2 patients 
and SD in 7 patients; unfortunately 5 patients discontinued 
therapy because toxicity and 6 discontinued therapy due 
to PD. Although this study was small, lenalidomide did show 
evidence of anti-tumor activity as evidenced by the patients 
with PR and SD [17]. In a larger multicenter phase II trial 
led by Fehniger et al., 38 patients with relapsed or refractory 
HL were treated with lenalidomide 25 mg/day on days 1-21 
of a 28-day cycle [18]. The primary endpoint was ORR, 
and treatment was continued until patients had either an 
unacceptable AE at the lowest dose (5 mg) or until developing 
PD. Of the 38 patients, 36 were evaluable, and of these, 
7 patients had responses (1 CR and 6 PRs, ORR 19%) and 
6 patients had SD (ORR cytostatic disease 33%). The most 
common grade 3-4 AEs included leukopenia, anemia, neu-
tropenia, and thrombocytopenia. In the largest study evaluat-
ing lenalidomide in HL to date, led by Boll et al., a total 
of 42 patients were given 25 mg lenalidomide daily for 21 
days of a 28 day cycle [19]. Of the 42 patients enrolled 
patients, 24 were eligible for analysis, and 50% had responded 
(1 CR and 11 PR) at the time of re-staging CT scan. This 
study, along with the others mentioned, suggests that lenali-
domide can be safely administered in heavily pre-treated 
HL patients similar to other relapsed lymphoma populations 
and holds promise as a single agent therapy in this patient Korean J Hematol 2012;47:8-16.
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Fig. 1. Proposed Mechanism of 
Action of Brentuximab Vedotin 
Antibody Drug Conjugate (ADC). 
Depiction of CD30 ligation by 
ADC followed by CD30-ADC in-
ternalization, lysosomal cleavage 
of linker and intracellular release of
anti-tubulin agent MMAE leading 
to cell cycle arrest and apoptosis. 
Abbreviation: RS, Reed-Sternberg.
population.
3. Everolimus
Inhibiting the mammalian target of rapamycin (mTOR) 
pathway has also been supported by preclinical data as a 
potential strategy for the treatment of HL. Most clinical 
data regarding mTOR inhibition and HL comes from studies 
with everolimus (RAD001), currently approved in the US 
for treating relapsed renal cell carcinoma [20, 21]. The activ-
ity of everolimus in relapsed/refractory HL was recently 
evaluated in a phase II trial published by Johnston et al., 
in which 19 patients with relapsed/refractory HL were given 
10 mg po Everolimus daily in a 4 week cycles. In this study, 
the median age was 37, patients had a median of 6 prior 
therapies, and 84% had prior auto-HCT (Table 2) [21]. The 
median duration of therapy was 7 months. The ORR was 
47%, including 8 patients with a PR and1 CR. Additionally, 
SD was reported in 8 patients. The median PFS was 7.2 
months, and OS was 25.2 months (from study entry). Grade 
3 or higher hematologic AE was experienced in 11 patients, 
including 6 patients with grade 3 anemia and 4 patients 
with grade 4 thrombocytopenia. Grade 3 or higher non-hem-
atologic AEs were experienced in 11 patients, including 3 
patients with grade 3 pulmonary toxicity and 1 with grade 
4 pulmonary toxicity. The high ORR shown with Everolimus 
in HL supports the hypothesis that the mTOR pathway may 
play an important role in the progression of HL, and that 
further studies investigating the safety and efficacy of these 
agents are warranted.
4. Rituximab
Rituximab, a monoclonal antibody directed against the 
cell-surface marker CD20 used extensively in NHL, has also 
been shown to have activity in HL. In a study published 
by Rassidakis et al., classic HL Reed-Sternberg (RS) cells 
expressed CD20 in 22% of 598 patients studied [22]. The 
use of rituximab in relapsed/refractory HL was evaluated 
by the M.D. Anderson Cancer Center, in a study that included 
22 patients, of whom all had nodular sclerosing type of 
HL (Table 2) [23]. The median age was 35 years, and 82% 
had prior transplant. Rituximab was given IV weekly (375 
mg/m
2) in the outpatient setting for 6 consecutive weeks. 
ORR was 22% (5 of 22 patients), including one CR and 
median remission duration was 7.8 months. Interestingly, 
objective response was seen regardless of CD20 expression 
on RS cells. Moreover, of the 7 patients with B symptoms, 
6 had resolution, and declines in serum IL-6 were seen after 
therapy. Because RS cells make up only approximately 5% 
of total tumor bulk in HL, it is thought that perhaps ritux-
imab’s effect in vivo may not be due to killing of RS cells, 
rather may be secondary to eliminating surrounding reactive 
B cells, leading to a decrease in cytokine and chemokine 
secretion [24]. Nevertheless, rituximab could be considered 
for those patients whose RS cells express CD20 and had 
exhausted other options.
5. Brentuximab vedotin
A cell surface marker that has attracted significant atten-
tion due to its role in the development of targeted monoclonal 
antibody therapies has been CD30, which is expressed in 
low levels in some normal tissues and abundantly in HL 
and anaplastic large cell lymphoma (ALCL) [25]. One of 
the first of such novel agents directed against this antigen 
is SGN-30, a chimerized IgG1 monoclonal antibody specific 
for CD30 [26]. Two phase I dose escalation trials of SGN-30 
demonstrated that drug was well tolerated and had anti-tu-
mor activity [27, 28]. Based on these results, a phase II 
trial was conducted by Forero-Torres et al., evaluating 38 Korean J Hematol 2012;47:8-16.
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HL and 41 ALCL patients who underwent 6 weekly IV 
infusions of SGN-30, followed by a 14-day break [29]. Of 
the 38 patients with HL, 11 patients (29%) had SD, however, 
no objective responses were observed. Although the ORR 
was 0% in HL patients who received with SGN-30, this 
work provided the foundation for the subsequent develop-
ment of brentuximab vedotin (SGN-35).
Brentuximab vedotin (SGN-35) is comprised of the pre-
viously described SGN-30, with the addition of a dipeptide 
linker that enables the attachment of Monomethyl auristatin 
E (MMAE), a potent anti-microtubule agent [26]. Specifi-
cally, brentuximab vedotin binds to CD30 on malignant RS 
cells, releases MMAE inside the cell via lysosomal degrada-
tion and once inside the cell, MMAE binds to tubulin within 
the cell and induces cell cycle arrest leading to apoptosis 
o f  t h e R S ce ll  (Fig. 1) [30]. In a phase I open label trial 
published by Younes et al., 45 patients with relapsed or 
refractory CD30+ lymphomas (42 patients with HL, 2 with 
ALCL and 1 with CD30+ angioimmunoblastic T Cell Lym-
phoma) were given brentuximab vedotin (0.1-3.6 mg/kg) 
every 3 weeks [31]. The AEs reported included peripheral 
neuropathy (16%) as well as nausea, diarrhea, fatigue, pyrexia 
and neutropenia. Of patients evaluated, 17 patients had ob-
jective responses (including 11 CRs) and 50% (6 of 12) of 
patients who received the MTD of 1.8 mg/kg had an objective 
response. The median duration of remission was 9.7 months. 
For patients with relapsed/refractory HL who had undergone 
previous therapies, 50% (13 of 26) had an objective response, 
including 9 CRs and 4 PRs. This response rate is particularly 
striking when compared with results with the un-conjugated 
SGN-30, in which no responses were observed [29, 31]. These 
encouraging phase I results led further studies investigating 
the safety and efficacy of brentuximab vedotin.
In a large, multi center phase II trial presented by Chen 
et al., the safety and efficacy of brentuximab vedotin were 
evaluated in patients with HL recurring after auto-HCT. 
A total of 102 patients were enrolled and given 1.8 mg/kg 
IV brentuximab vedotin every 21 days as outpatient 30 mi-
nute infusions (Table 2) [30]. Patients had a median of 3.5 
(1-13) prior systemic chemotherapy treatments (excluding 
auto-HCT). Over 70% of patients had primary refractory 
disease, and 42% had not responded to most recent prior 
therapy. The primary endpoint of the study was ORR per 
an independent review facility (IRF) in accordance with 
the Revised Response Criteria for Malignant Lymphoma [32]. 
Per the IRF, the ORR was 75% (76 of 102 patients), with 
CR in 34% (35 of 102). For patients with CR, the median 
DOR had not been reached (0.3+ to 61.4+ weeks). The major 
AEs occurring in ≥15% of patients were peripheral sensory 
neuropathy, fatigue, nausea, diarrhea and neutropenia. Grade 
3 AEs occurring in more than 5% of patients were anemia, 
thrombocytopenia, neutropenia and peripheral sensory 
neuropathy. These results demonstrating an ORR of 75% 
in the relapsed/refractory HL population led to the approval 
of this agent in the US for HL recurring after auto HCT 
or for those with relapsed disease after ≥2 regimens who 
are not auto-HCT candidates.
Brentuximab vedotin has also been evaluated in a number 
of other settings, including for longer-term use, in combina-
tion with chemotherapeutic agents and for improved disease 
control prior to RIC allo-HCT. Forero-Torres et al., in a 
recent retrospective analysis, evaluated 15 patients who had 
received more than 16 consecutive cycles of brentuximab 
vedotin, dosed at either 1.2 or 1.8 mg/kg of brentuximab 
vedotin every 3 weeks, and found that the safety profile 
did not meaningfully change [33]. Studies evaluating the 
combination of this agent with standard chemotherapeutic 
regimens, such as ABVD and AVD (Adriamycin, vinblastine 
and dacarbazine) are currently underway [34]. Brentuximab- 
vedotin also has potential use for improving disease control 
in patients with relapsed/refractory HL prior to transplant, 
and is currently being evaluated for this purpose. A retro-
spective analysis by Chen et al., described 16 patients from 
the Fred Hutchinson Cancer Research Center (FHCRC)/ 
Seattle Cancer Care Alliance (SCCA) (N=4) and the City 
of Hope National Medical Center (COH) (N=12) with re-
lapsed/refractory HL who underwent RIC allo-HCT follow-
ing treatment with brentuximab vedotin [35]. At COH, the 
1-year OS was 100% and PFS was 90% with 1 relapse, at 
the FHCRC/SCCA all 4 patients were progression free at 
a follow up at 7.2 months. There appeared to be no increased 
risk of EBV/CMV infections, no delay in engraftment and 
no grade III-IV acute graft-versus-host disease (GVHD) 
though one patient experienced extensive chronic GVHD 
to date. These results imply that brentuximab vedotin has 
the potential to improve pre-transplant disease control prior 
to RIC allo-HCT that hypothetically could translate into 
improve long-term disease-free survival (DFS), without in-
curring added risk of infection or delayed engraftment. The 
full potential of brentuximab vedotin for use in HL is still 
emerging, and future trials will be needed to fully define 
the optimal use of this agent in HL.
ALLOGENEIC TRANSPLANT
Achieving lasting cure in patients with relapsed/refractory 
HL following auto-HCT remains difficult, and while novel 
single agent therapies have shown promise, traditional think-
ing suggests that these therapies do not have the same poten-
tial for cure as allo-HCT. However, an allo-SCT still poses 
multiple challenges, including identification of a donor, short 
and long-term toxicity, and continued risk of relapse [36]. 
Fully myeloablative allo-HCTs have also been evaluated, 
but an association with early transplant related mortality 
(TRM) have limited their appeal [37, 38]. An alternative 
allo-HCT strategy that is more commonly employed in this 
setting is RIC allo-HCT. The following section will review 
recent advances and challenges of RIC allo HCT in patients 
with relapsed/refractory HL.
1. Conditioning intensity
In an informative paper published by Sureda et al. in 
2008, RIC allo HCT was compared with full myeloablative Korean J Hematol 2012;47:8-16.
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Table 3. Selected series of reduced intensity allogeneic transplant for relapsed Hodgkin lymphoma.
First author
No. of 
patients
Donor type
Conditioning 
regimen
Med. 
age
No. of 
prior Rx
Prior 
trans-
plant
a)
Chemo-
Ref.
disease 
NRM PFS OS
Sureda et al. [39]   89 (RIC) 86.5% MRD RIC regimens
b) 30 84%≥3 62%    55%  24% at 18% at 28% at
13.5% MUD  3 yrs  5 yrs  5 yrs
Anderlini et al. [40]   40 50% MUD RIC: 35% Flu/Cy 31      5 75%    35%  22% at 32% at 61% at
50% HLA haplo  +ATG; 65% Flu-M  18 mos  18 mos  18 mos
Anderlini et al. [41]   58 57% MUD RIC: Flu-M 32      5 83%    48%  15% at 32% at 64% at
43% MRD  2 yrs  2 yrs  2 yrs
Burroughs et al. [36]   90 27% MUD NMT: TBI 2Gy +/- 32      5 92% 21-43%  8-21% 23-51% 53-58%
42% MRD  Flu; TBI/Flu/Cy  at 2 yrs  at 2 yrs  at 2 yrs
31% HLA haplo  (haplo only)
Robinson et al. [42]  285 33% MUD RIC: 79.5% Flu 31.2       4 80%    25%  21.1% 25% at 29% at
3% MMUD  based; 16% TBI  at 3 yrs  3 yrs  3 yrs
60% MRD  based
4% MMRD
a)Excluding auto-HCT, 
b)Included regimens under RIC definition: carmustine 300 mg/m
2 IV, etoposide 600-800 mg/m
2 IV, cytarabine 800-1,600 
mg/m
2 IV, melphalan 100-140 mg/m
2 IV (BEAM regimen); Flu plus 2-4 Gy TBI or 1-2 low dose alkylating agents.
Abbreviations: RIC, reduced intensity chemotherapy; No., number; Ref., refractory; NRM, non-relapse mortality; PFS, progression free survival;
OS, overall survival; yrs, years; NMT, nonmyeloablative therapy; TBI, total body irradiation; mos, months; MUD, matched unrelated donor; 
MMUD, mis-matched unrelated donor; MRD, matched related donor; MMRD, mis-matched related donor; HLA haplo, HLA haploidentical 
donor; Flu, fludarabine; Cy, cyclophosphamide; ATG, antithymocyte globulin; Flu-M, fludarabine-melphalan.
allo-HCT (Table 3) [39]. In this retrospective study, a total 
of 168 patients with relapsed/refractory HL were evaluated, 
with 89 receiving RIC and 79 receiving myeloablative 
conditioning. Patients in the RIC group had improved 
non-relapse mortality (NRM) compared with the conven-
tional group: at 3 months NRM was 15% (RIC) vs. 28% 
(conventional), and at 1 year was 23% (RIC) vs. 46% (conven-
tional). In terms of relapse, the two groups were similar: 
at 5 years, OS was 28% (RIC) vs. 22% (conventional), and 
5 year PFS was 18% (RIC) vs. 20% (conventional). Factors 
in both groups associated with an increased in NRM were 
chemorefractory disease (relative risk, RR=1.64), conven-
tional conditioning regimen (RR=2.85) and previously failed 
auto-HCT (RR=1.9). NRM was especially high in those pa-
tients who had failed prior auto-HCT who underwent full 
myeloablative transplant (RR=3.7). These data imply that 
myeloablative preparative regimens, especially in patients 
who have undergone prior auto-HCT, are associated with 
higher toxicity and that for most patients, may not be of 
added benefit. Overall results from both arms indicate that 
only about 1 in 5 patients will achieve long-term DFS regard-
less of conditioning regimen, and that relapse is problematic 
in both groups.
2. Choice of RIC regimen
A number of groups have focused on identifying a regimen 
for RIC allo-HCT that could improve outcomes and to date, 
no firm conclusions can be drawn. Anderlini et al. published 
a small, single institution retrospective analysis comparing 
fludarabine-cyclophosphamide (Flu-Cy)+ATG with a more 
intensive regimen with fludarabine-melphalan (Flu-M) in 
patients with relapsed/refractory HL undergoing RIC al-
lo-HCT (Table 3) [40]. In this study, 40 patients received 
either a matched unrelated donor (MUD, N=20) or HLA- 
identical sibling donor (N=20), and patients received one 
of the two previously described RIC regimens. Short term 
TRM was promising for the groups overall: 5% at day 100 
and 22% at 18 months. Of the original 40 patients, a total 
of 8 patients died from TRM and another 8 patients died 
from PD. Flu-M was shown to have a better OS than the 
Flu-Cy+ATG regimen (73% vs. 39% at 18 months) [40]. 
This same investigator published a prospective study further 
evaluating the outcome of Flu-M as a RIC regimen in allo 
HCT for patients with relapsed/refractory HL. In this study, 
58 patients underwent RIC allo HCT with Flu-M with both 
MUD (N=33) and matched related donor (MRD, N=25) [41]. 
TRM was 7% at day 100 and 15% at 2 years. Of the 58 
patients, 20 had died, including 14 from PD and 3 from 
GVHD. Interestingly, no significant differences were found 
in OS, PFS, PD or TRM between the MUD vs. MRD groups. 
Though the non-randomized nature of these comparisons 
must be acknowledged, these studies showed that Flu-M 
based RIC regimens for allo- H C T  m a y  b e  s u p e r i o r  t o  
Flu-Cy+ATG based RIC regimens and that there do not ap-
pear to be inferior outcomes when an MUD is employed. 
Short of these data, substantial formal comparisons of RIC 
regimens are limited for HL, and, thus, most patients are 
treated with approaches that are standard for a given 
institution.
3. Donor source
Determining whether donor source affects outcome in 
patients with relapsed/refractory HL undergoing RIC al-
lo-HCT has been a clinically important question. As described 
above, Anderlini was not able to show a difference between 
MRD and MUD [41]. To specifically address this question, 
Burroughs et al. conducted a single institution retrospective 
analysis that evaluated differences in donor type and outcome Korean J Hematol 2012;47:8-16.
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(Table 3) [36]. In this study, 90 patients with HL received 
an allo-HCT from either a MUD (N=24), HLA-haploidentical 
related donor (N=28) or MRD (N=38). Most patients had 
failed prior high dose autologous/syngeneic HCT (92%), had 
undergone radiation (83%), and had a median of 5 (2-10) 
prior regimens. Nonmyeloablative preparative regimens in-
cluded 2 Gy total body irradiation (TBI) alone (MRD), or 
2 Gy TBI combined with Flu 30 mg/m
2/day on days -4, 
-2 (MRD, MUD) or finally Cy 14.5 mg/kg/day on days -5, 
-6 (HLA haploidentical related recipients) combined with 
Flu 30 mg/m
2/day and 2 Gy TBI. This was followed by 
post-grafting immunosuppression with either cyclosporine/ 
tacrolimus or mycophenolate mofetil (MMF). At 25 months 
m e d i a n  f o l l o w  u p ,  O S  r a n g e d  from 53-58%, PFS ranged 
from 23-51%, and relapsed/PD ranged from 40-63%. HLA- 
haploidentical related recipients had significantly lower 
NRM compared with MRD recipients. Moreover, HLA-hap-
loidentical related recipients also had significantly decreased 
risk of relapse compared with the other groups. The incidence 
of acute GVHD (grades III-IV) and chronic GVHD was 16% 
and 50% respectively in the MRD group, 11% and 35% 
in the HLA-haploidentical related group and 8% and 63% 
in the MUD group [36]. This study further supports that 
RIC/NMT regimens are associated with lower NRM, and 
also suggests that alternative donor sources can be considered 
an option in these heavily pre-treated patients who may 
have a limited time frame to proceed to HCT. Disease pro-
gression, however, remains a challenge regardless of donor 
type [36].
4. Factors associated with outcome
Identifying prognostic factors that predict outcome in pa-
tients with relapsed/refractory HL undergoing RIC allo-HCT 
is especially important given the high reported relapse rates. 
A retrospective analysis published by Robinson et al., eval-
uated 285 patients, 25% with chemorefractory disease and 
80% who had prior auto-HCT (Table 3) [42]. At a median 
follow up of 26 months, 55% of patients had died (159 of 
285), and relapse rates were high with 41% at 1 year, 53% 
at 2 years and 59% at 5 years. At 3 years, PFS was 25% 
and OS was 29%. Improved OS was seen in patients who 
had chemosensitive disease, had good performance status, 
entered allo-HCT in CR, and had transplants other than 
sex mismatched male recipients and CMV-/- transplants. 
Improved PFS was associated with similar factors affecting 
OS, including CR at the time of allo-HCT, chemosensitive 
disease, good performance status and transplant other than 
sex mismatched male recipients. Additionally, patients who 
had relapsed within six months of prior auto-HCT were 
also associated with lower PFS and higher relapse rate. Acute 
GVHD developed in 49% of patients, and was associated 
with worse outcomes: higher NRM, lower PFS and OS, and 
no improvement in risk of relapse. At 100 days, 38% (87) 
patients developed chronic GVHD, although 13% (5 patients) 
were unable to be evaluated [42]. Data from this study and 
others can be used to help predict post-transplant outcomes 
and assist in deciding which patients may achieve the most 
benefit from this procedure.
5. Relapse after RIC allo-HCT
As shown by prior studies reported in this review, there 
are some patients with relapsed/refractory HL who achieve 
lasting cure with RIC allo-HCT, although many patients 
unfortunately suffer PD. To better counsel patients in this 
situation and to evaluate specific management strategies in 
this setting, Ram et al. described 101 patients with lymphoma 
who had relapses after RIC and allo-HCT [43]. This group 
included 26 patients with relapsed/refractory HL, 50% (13 
patients with HL) of whom had prior auto-HCT. HL patients 
tended to relapse later than those with other lymphoma 
histologies (6.3 months vs. 3.4 months for indolent NHL 
and 1.3 m for aggressive NHL). Relapse occurred much sooner 
in the HL group with prior auto-HCT (median 4.6 months) 
compared with patients who did not have prior auto-HCT 
(median 12 months). The estimated 3 year OS after relapse 
in HL patients was 47%. Patients with HL, despite a longer 
time to initial relapse relative to indolent NHL, were shown 
to have the greatest risk of PD even after response to initial 
therapy for post RIC allo-HCT relapse. Thus, further strat-
egies to achieve lasting remission following RIC allo-HCT 
are needed. One potential option that has been evaluated 
includes brentuximab vedotin (discussed earlier in this re-
view), which was shown by Gopal et al., in a multicenter 
series of 25 patients with HL recurring following allo-HCT, 
to yield a 50% response rate in evaluable patients [44]. 
Nevertheless, despite interest in this area, improved strategies 
are still need for management of post allo-HCT relapse. 
CONCLUSIONS
In summary, the treatment of relapsed/refractory HL has 
seen the development of significant advances in the last 
decade. The development of novel primarily gemcita-
bine-based chemotherapeutic combinations as well as dem-
onstration of activity of varied classes of agents including 
HDAC inhibitors (panobinostat), immunomodulatory agents 
(lenalidomide), mTOR inhiobitors (everolimus), novel cyto-
toxics (bendamustine), monoclonal antibodies (rituximab), 
and antibody-drug conjugates (brentuximab vedotin) hold 
promise that the natural history of this challenging clinical 
situation can be improved. To date, most data suggest that 
long-term DFS for HL recurring after auto-HCT can be ob-
tained in a minority of patients following allo-HCT, though 
even with this procedure toxicity and continued relapse re-
mains a major hurdle. Future directions will likely include 
moving these agents earlier into the treatment paradigm 
with the hopes to reduce the fraction of patients with relapse 
and to optimize the use of these and forthcoming strategies 
to best improve outcomes of those who continue to suffer 
disease progression.Korean J Hematol 2012;47:8-16.
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